Neuroendocrine Cancer Market to Grow at 10.6% CAGR | Precision Medicine & Targeted Therapies Lead | Novartis AG, Pfizer Inc., Ipsen

The Neuroendocrine Cancer Market is estimated to reach at a CAGR of 10.6% during the forecast period (2024-2031).

Neuroendocrine cancer arises from neuroendocrine cells, which produce hormones and regulate body functions. These tumors can occur in the pancreas, lungs, or gastrointestinal tract. They vary from slow-growing to highly aggressive forms. Treatment options include surgery, targeted therapy, somatostatin analogs, and radionuclide therapy. Early detection improves prognosis, though symptoms are often nonspecific. Ongoing research focuses on molecular profiling and immunotherapy for better treatment outcomes.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Neuroendocrine Cancer Market Landscape:- https://datamintelligence.com/download-sample/neuroendocrine-cancer-market?Ranjith

☛ Neuroendocrine Cancer Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In July 2025, Ipsen Biopharmaceuticals reported positive Phase 3 results for Somatuline (lanreotide) in advanced neuroendocrine tumors, demonstrating improved progression-free survival and symptom control.

✅ In June 2025, Novartis expanded the use of Lutathera (177Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors, targeting enhanced tumor uptake and reduced toxicity.

✅ In May 2025, Lexicon Pharmaceuticals initiated clinical trials for novel small-molecule inhibitors targeting specific neuroendocrine tumor pathways, aiming to improve efficacy in resistant cases.

Japan: Recent Industry Developments

✅ In July 2025, Takeda Pharmaceutical advanced Phase 2 trials for targeted therapies in pancreatic and gastrointestinal neuroendocrine tumors, focusing on personalized treatment approaches.

✅ In June 2025, Daiichi Sankyo developed antibody-drug conjugates (ADCs) for neuroendocrine cancers, combining targeted delivery with potent cytotoxic activity.

✅ In May 2025, Chugai Pharmaceutical partnered with Japanese hospitals to implement AI-assisted diagnostic and monitoring tools for early detection and therapy optimization in neuroendocrine tumors.

☛ Neuroendocrine Cancer Market Competitive Landscape:

Novartis AG, Pfizer Inc., Ipsen, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., Exelixis, Inc., Advanced Accelerator Applications, Argos Therapeutics Inc.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/neuroendocrine-cancer-market?Ranjith

☛ Segments Covered in the Neuroendocrine Cancer Market:

By Drug Type: Sunitinib Malate, Everolimus, Lanreotide, Octreotide, Others.

By Treatment: Surgery, Chemotherapy, Targeted Therapy, Radiotherapy, Other Medications.

By End-User: Hospitals, Oncology Centers, Others.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Neuroendocrine Cancer Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=neuroendocrine-cancer-market?Ranjith

☛ Regional Analysis for Neuroendocrine Cancer Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.